Abstract
Background
Clinically relevant aortic dilatation (>40 mm) and increased cardiovascular risk are common among retired professional American‐style football athletes. Among younger athletes, the effect of American‐style football participation on aortic size is incompletely understood. We sought to determine changes in aortic root (AR) size and associated cardiovascular phenotypes across the collegiate career.
Methods and Results
This was a multicenter, longitudinal repeated‐measures observational cohort study of athletes across 3 years of elite collegiate American‐style football participation. A total of 247 athletes (119 [48%] Black, 126 [51%] White, 2 [1%] Latino; 91 [37%] linemen, 156 [63%] non‐linemen) were enrolled as freshmen and studied at pre‐ and postseason year 1, postseason year 2 (N=140 athletes), and postseason year 3 (N=82 athletes). AR size was measured with transthoracic echocardiography. AR diameter increased over the study period from 31.7 (95% CI, 31.4–32.0) to 33.5 mm (95% CI, 33.1–33.8; P<0.001). No athlete developed an AR ≥40 mm. Athletes also demonstrated increased weight (cumulative mean Δ, 5.0 [95% CI, 4.1–6.0] kg, P<0.001), systolic blood pressure (cumulative mean Δ, 10.6 [95% CI, 8.0–13.2] mm Hg, P<0.001), pulse wave velocity (cumulative mean Δ, 0.43 [95% CI, 0.31–0.56] m/s, P<0.001), and left ventricular mass index (cumulative mean Δ, 21.2 [95% CI, 19.2–23.3] g/m2, P<0.001), and decreased E′ velocity (cumulative mean Δ, −2.4 [95%CI, −2.9 to −1.9] cm/s, P<0.001). Adjusting for height, player position, systolic blood pressure, and diastolic blood pressure, higher weight (β=0.030, P=0.003), pulse wave velocity (β=0.215, P=0.02), and left ventricular mass index (β=0.032, P<0.001) and lower E′ (β=−0.082, P=0.001) were associated with increased AR diameter.
Conclusions
Over the collegiate American‐style football career, athletes demonstrate progressive AR dilatation associated with cardiac and vascular functional impairment. Future studies delineating aortic outcomes are necessary to determine whether AR dilation is indicative of maladaptive vascular remodeling in this population.
Keywords: American football, aorta, echocardiography, exercise
Subject Categories: Echocardiography, Exercise, Risk Factors
Nonstandard Abbreviations and Acronyms
- AR
aortic root
- ASF
American‐style football
- PWV
pulse wave velocity
Clinical Perspective.
What Is New?
Aortic root enlargement occurs with American‐style football participation.
This aortic enlargement is associated with multiple maladaptive measures of cardiovascular health including arterial stiffening, increased body weight, and decreased diastolic function.
What Are the Clinical Implications?
American‐style football athletes with clinically relevant aortic dilatation (>40 mm) warrant more frequent clinical monitoring and additional evaluation for underlying cardiovascular risk factors.
Clinically significant aortic dilatation predicts acute aortic events in the general population. 1 However, recent cross‐sectional data suggest a higher than expected prevalence of clinically significant aortic dilatation (defined as >40 mm in diameter) among healthy aging athletes. 2 , 3 The clinical significance of these observations is uncertain and among youthful athletes, the effect of sport participation on aortic root (AR) size is also poorly understood. 4 , 5 , 6 Although prior cross‐sectional data have shown AR size is slightly larger in young athletes, 5 , 6 , 7 , 8 there is a dearth of longitudinal data characterizing the impact of sport participation on aortic dimensions.
Among retired professional American‐style football (ASF) athletes, a recent study reported a 30% prevalence of clinically significant aortic dilatation. 3 Although clinical outcomes detailing the prevalence of acute aortic syndromes are lacking in this population, it is well established that retired ASF athletes, particularly those who had increased playing‐time body‐mass index or who were linemen position players, experience increased cardiovascular disease mortality compared with the general population. 9 , 10 Early markers of cardiovascular risk are also common in young, collegiate ASF athletes with increased incident hypertension 11 , 12 and the development of a maladaptive cardiovascular phenotype characterized by relative arterial stiffening, reduced diastolic function, and concentric left ventricular (LV) hypertrophy. 13 , 14 , 15 , 16 Whether active ASF participation also leads to changes in aortic size has not previously been analyzed.
We therefore sought to investigate whether ASF participation leads to AR dilatation, defined in this study as any longitudinal increase in AR diameter. We hypothesized that ASF athletes would demonstrate progressive AR dilatation over the course of collegiate ASF participation and that AR dilatation would be associated with previously described maladaptive ASF cardiovascular phenotypes. 15 To address this hypothesis, we performed a multicenter, longitudinal repeated measures observational cohort study of collegiate ASF athletes with rigorous cardiovascular phenotyping over the course of the competitive collegiate ASF career.
METHODS
College ASF athletes ≥18 years old were recruited from National Collegiate Athletic Association Division‐I programs at Georgia Institute of Technology (Atlanta, GA) and Furman University (Greenville, SC) and studied between 2014 and 2019. Clinical characteristics, anthropometric measurements, transthoracic echocardiography, and vascular applanation tonometry were prospectively and longitudinally captured for all study participants over this time period. The Emory Institutional Review Board approved all aspects of this study and all participants provided written informed consent. Analytic methods are available upon reasonable request to the corresponding author. Due to potential for subject identification, data are not available for public use.
Study Population
ASF athletes were initially recruited as freshmen each year of the study in parallel with the academic calendar. Participants were then followed prospectively throughout their college career and during the study period. For the freshman season, athletes were studied at 2 time points that included the preseason (baseline) and the immediate conclusion of the season (postseason year 1), approximately 5 to 6 months later. For the sophomore season, athletes were studied at just 1 time point (postseason year 2), approximately 1 year after postseason year 1, and for the junior season, athletes were again studied at just 1 time point (postseason year 3), approximately 1 year after postseason year 2 (Figure 1). Two time points for freshman ASF athletes were included because of the significant cardiovascular plasticity previously demonstrated among first‐year college athletes in response to athletic training. 14 Because ASF athletes at the participating institutions engage in consistent levels of ASF training throughout the calendar year after the freshman season, only annual postseason study time points were captured beyond the first year (postseason years 2 and 3). Athletes with known hypertension on pharmacotherapy were excluded. Athletes with suspected genetic aortopathy, including those with bicuspid aortic valves, and those who did not complete the first competitive ASF season were also excluded.
Figure 1. Subject enrollment and prospective follow‐up.
Subjects were required to abstain from exercise for >24 hours before data collection. Clinical data including age (years), height (centimeters), current medication use, family history of cardiovascular disease or sudden death, and self‐reported race and ethnicity were collected at baseline. Player position was classified as either lineman or non‐lineman as previously proposed. 17 All athletes were subject to performance‐enhancing drug testing protocols as per National Collegiate Athletic Association guidelines (generally 1–2 times per season). Weight (kilograms), systolic blood pressure (mm Hg), and diastolic blood pressure (mm Hg) were collected at all time points. Blood pressure was measured after ≥15 minutes of rest using a manual aneroid sphygmomanometer and an appropriately sized cuff and recorded as the average of 3 measurements.
Two‐Dimensional Transthoracic Echocardiography
Transthoracic echocardiography was performed using a commercially available system (Vivid‐I; GE Healthcare, Milwaukee, WI) at all study time points. Two‐dimensional and tissue‐Doppler imaging from standard parasternal and apical positions were performed by experienced sonographers, who were consistent throughout the years of this study. Frame rates were individualized per study for optimal image quality between 60 and 100 Hz. All information was stored digitally, and blinded, poststudy offline data analysis (EchoPAC version 7; GE Healthcare) was performed by study investigators (J.V.T., J.H.K.). Definitions of normality for cardiac structure and function were adopted from the most recent guidelines. 18 LV mass was measured using the area‐length method (accounts for LV morphology in both the short and long axis) and indexed to body surface area, and LV ejection fraction was calculated using the modified biplane technique. 18 Comprehensive assessment of cardiac diastolic function using tissue‐Doppler imaging was performed, and tissue velocities (E′, A′, and S′) were measured from color‐coded images at the lateral and septal mitral annulus. E′ was then reported as the average value of the septal and lateral annular measurements. AR diameter was measured in the standard parasternal long‐axis view at end‐diastole using the leading edge to leading edge method 19 Absolute AR diameter, rather than AR diameter indexed to body size is reported because AR size plateaus at the extremes of body size. 20 Not only is this applicable to ASF athletes, but additional and deliberate weight gain is also a hallmark of competitive ASF training. 21
AR Measurement Variability
For quality consistency and assurance, AR diameter was measured in 48 randomly selected echocardiographic studies (12 from each study time point) by a separate study investigator (B.R.W.) who was blinded to all previous measurements. Pearson correlation analysis yielded an r=0.91 (P<0.001). A paired t test used to assess discrepancies among observations revealed no significant variability among observers (mean difference 0.06 mm, P=0.7). Bland–Altman analysis resulted in a mean bias of 0.06 mm (95% CI, −0.25 to 0.37) with upper and lower limits of agreement 2.17 and −2.05, respectively.
Vascular Applanation Tonometry
Arterial stiffness was measured at all time points using high‐fidelity applanation tonometry (SphygmoCor; Atcor Medical, Sydney, Australia), which records sequential high‐quality pressure waveforms at peripheral pulse sites. The primary measure of arterial function was the carotid–femoral pulse wave velocity (PWV), the gold‐standard index of arterial stiffness, 22 measured as previously described. 13
Statistical Analysis
Baseline continuous variables are presented as the mean±SD, and categorical variables as percentages. Separate linear mixed‐effects models were constructed to evaluate for longitudinal changes in clinical and cardiovascular measurements, with time being the categorical (baseline, year 1, 2, and 3) independent variable adjusting for player position (non‐lineman or lineman). The predicted marginal means with 95% CIs for the clinical and cardiovascular measurements were reported for each time point. Type III tests of fixed effects were used to evaluate the overall change in each selected variable over the study period. To assess for factors associated with AR diameter, a linear mixed‐effects model was constructed with independent variables including height, player position, weight, systolic blood pressure, diastolic blood pressure, PWV, E′, and LV mass index. All measurements at all available time points for subjects were included in this model. Participant specific random intercepts were incorporated to account for within‐participant correlations. Analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC). A P value of ≤0.05 was considered significant.
RESULTS
Baseline Characteristics
Between 2014 and 2019, 272 collegiate freshman ASF athletes were serially enrolled in this study. 2 athletes were then excluded, 1 due to the presence of bicuspid aortic valve with associated aortopathy and 1 athlete due to clinically significant aortic dilatation and family history of Marfan syndrome. The final analysis included 247 athletes who completed at least 1 competitive ASF season. Due to the rolling nature of study enrollment aligned with the collegiate academic calendar, 247 were analyzed at baseline and postseason year 1, 140 were analyzed at postseason year 2, and 82 were analyzed at postseason year 3 (Figure 1). At baseline (preseason year 1), the final study cohort was composed of N=119 Black athletes (48%), N=126 White athletes (51%), and N=2 athletes of Latino self‐identified race and ethnicity (1%). N=91 (37%) were linemen and N=156 (63%) non‐linemen (Table 1). There was no significant change in the proportion of linemen versus non‐linemen across the study time points with subject attrition (P=0.45).
Table 1.
Baseline Characteristics
Characteristic | N=247 Athletes |
---|---|
Age, y | 18±0.4 |
Race and ethnicity | 119 (48%) Black |
126 (51%) White | |
2 (1%) Latino | |
Player position | 91 (37%) Linemen |
156 (63%) Non‐linemen | |
Height, cm | 185±6 |
Weight, kg | 100.2±19.1 |
Systolic blood pressure, mm Hg | 128±12 |
Diastolic blood pressure, mm Hg | 76±10 |
Longitudinal Changes in Cardiovascular Phenotypes and AR Diameter
Longitudinal changes in cardiovascular phenotypes for all study participants are summarized in Table 2. Adjusting for player position, athletes demonstrated increased weight (cumulative mean Δ, 5.0 [95% CI, 4.1–6.0] kg, P<0.001), systolic blood pressure (cumulative mean Δ, 10.6 [95% CI, 8.0–13.2] mm Hg, P<0.001), and PWV (cumulative mean Δ, 0.43 [95% CI, 0.31–0.56] m/s, P<0.001) from baseline to postseason year 3. Athletes also demonstrated cardiac changes including increased LV mass index (cumulative mean Δ, 21.2 [95% CI, 19.2–23.3] g/m2, P<0.001) and decreased E′ (cumulative mean Δ, −2.4 [95% CI, −2.9 to −1.9] cm/s, P<0.001). AR diameter increased over the 3‐year study period (cumulative mean Δ, 1.8 [95% CI, 1.5–2.0] mm, P<0.001) from 31.7 (95% CI, 31.4–32.0) to 33.5 mm (95% CI, 33.1–33.8). In considering just the N=82 who completed 3 full years of collegiate ASF, AR diameter also significantly increased from 31.7 mm (95% CI, 31.1–32.2) to 33.5 mm (95% CI, 33.0–34.1; P<0.001) (Figure 2). In considering differences in the change in AR size by player position (linemen versus non‐linemen), there was no interaction between player position and AR size across study time points (P=0.53). Finally, no athlete started with or developed an AR ≥40 mm during the study period or demonstrated any significant aortic regurgitation at any time point.
Table 2.
Longitudinal Changes in Clinical and Cardiovascular Measurements
Characteristic | Baseline (N=247) | Year 1 postseason (N=247) | Year 2 postseason (N=140) | Year 3 postseason (N=82) | P value |
---|---|---|---|---|---|
Weight, kg | 100.7 (99.2–102.2) | 102.4 (100.9–103.9) | 103.9 (102.3–105.4) | 105.7 (104.1–107.4) | <0.001 |
Systolic BP, mm Hg | 128.5 (126.9–130.1) | 133.0 (131.4–134.6) | 133.9 (131.9–135.9) | 139.1 (136.6–141.6) | <0.001 |
Diastolic BP, mm Hg | 76.0 (74.7–77.2) | 76.3 (75.1–77.6) | 77.6 (76.0–79.2) | 78.3 (76.3–80.3) | 0.12 |
LV mass, g | 204.0 (200.2–207.8) | 231.1 (227.3–234.9) | 241.8 (237.3–246.2) | 258.9 (253.6–264.1) | <0.001 |
LV mass/body surface area, g/m2 | 89.8 (88.4–91.2) | 101.0 (99.6–102.3) | 104.5 (102.8–106.2) | 111.0 (109.0–113.1) | <0.001 |
LV internal diameter at end‐diastole, mm | 52.2 (51.6–52.7) | 53.2 (52.6–53.7) | 53.6 (53.0–54.2) | 54.2 (53.6–54.9) | <0.001 |
Mean wall thickness, mm | 9.0 (8.9–9.1) | 10.0 (9.9–10.1) | 10.3 (10.2–10.5) | 10.8 (10.7–11.0) | <0.001 |
Relative wall thickness | 0.35 (0.34–0.36) | 0.38 (0.37–0.39) | 0.39 (0.39–0.40) | 0.40 (0.39–0.41) | <0.001 |
LV ejection fraction, % | 61.4 (60.8–62.0) | 60.1 (59.5–60.8) | 60.4 (59.6–61.3) | 60.0 (58.9–61.0) | 0.01 |
E′, cm/s | 16.3 (16.0–16.6) | 15.2 (14.9–15.5) | 14.6 (14.2–15.0) | 13.9 (13.4–14.4) | <0.001 |
Pulse wave velocity, m/s | 5.0 (4.9–5.1) | 5.2 (5.1–5.3) | 5.4 (5.3–5.5) | 5.4 (5.3–5.5) | <0.001 |
Aortic root diameter, mm | 31.7 (31.4–32.0) | 32.4 (32.1–32.7) | 33.0 (32.6–33.3) | 33.5 (33.1–33.8) | <0.001 |
Mean wall thickness: [interventricular septum+posterior wall]/2. E′, average of early diastolic septal and lateral tissue‐Doppler velocities. Relative wall thickness: mean wall thickness/LVIDD. Mean (95% CI), adjusted for player position. BP indicates blood pressure; and LV, left ventricular.
Figure 2. Longitudinal aortic root diameters among athletes present at all time points.
Aortic root size increased over the study period. Violin plot interpretation: the heavy dashed line represents the median aortic root size. The lighter dashed lines represent the interquartile range, and the width represents distribution of aortic root size.
Factors Associated With AR Diameter
In univariate analysis including all measurements per variable at all available time points for subjects (Table 3), height (β=0.108, P<0.001), lineman player position (β=1.57, P<0.001), and higher weight (β=0.056, P<0.001), systolic blood pressure (β=0.028, P<0.001), diastolic blood pressure (β=0.011, P=0.047), PWV (β=0.624, P<0.001), and LV mass index (β=0.045, P<0.001) were associated with larger AR diameter. In addition, lower E′ (β=−0.189, P<0.001) was associated with larger AR diameter. In multivariable mixed‐effects linear regression analysis including all measurements at all available time points for subjects, higher weight (β=0.030, P=0.003), PWV (β=0.215, P=0.02), and LV mass index (β=0.032, P<0.001), and lower E′ (β=−0.082, P=0.001) were associated with increased AR diameter (Table 3).
Table 3.
Factors Associated With Aortic Root Size
Characteristic | Univariate | Multivariable | ||
---|---|---|---|---|
β (95% CI) | P value | β (95% CI) | P value | |
Height, m | 0.108 (0.062 to 0.154) | <0.001 | 0.030 (−0.025 to 0.084) | 0.3 |
Player position | 1.57 (0.97 to 2.17) | <0.001 | 0.021 (−0.812 to 0.853) | 0.9 |
Weight, kg | 0.056 (0.043 to 0.069) | <0.001 | 0.030 (0.011 to 0.050) | 0.003* |
Systolic BP, mm Hg | 0.028 (0.019 to 0.037) | <0.001 | 0.007 (−0.002 to 0.017) | 0.1 |
Diastolic BP, mm Hg | 0.011 (0.00 to 0.023) | 0.047 | −0.003 (−0.015 to 0.008) | 0.5 |
Pulse wave velocity, m/s | 0.624 (0.439 to 0.809) | <0.001 | 0.215 (0.029 to 0.402) | 0.02* |
E′, cm/s | −0.189 (−0.238 to −0.139) | <0.001 | −0.082 (−0.132 to −0.032) | 0.001* |
Left ventricular mass/body surface area, g/m2 | 0.045 (0.037 to 0.053) | <0.001 | 0.032 (0.023 to 0.041) | <0.001* |
BP indicates blood pressure.
These values are statistically significant with P<0.05.
DISCUSSION
To our knowledge, this is the first prospective and longitudinal analysis of AR size, inclusive of other cardiovascular structural and functional measures, in a young, athletic population. Key findings are summarized as follows. First, progressive AR enlargement occurs throughout the entirety of collegiate ASF participation. Second, increased AR size is associated with established ASF‐related maladaptive cardiovascular phenotypes including vascular stiffening 13 and reduced diastolic function. 14 , 15 Taken together, mild AR dilatation appears to have a causal relationship with collegiate ASF participation and may represent an additional maladaptive cardiovascular phenotypes observed in this athletic population.
Data ascertaining the effect of sport participation on aortic size in young athletes are limited and come primarily from cross‐sectional and case–control studies. 5 , 6 , 23 , 24 In a meta‐analysis from Iskandar and Thompson, aortic diameter was largest at the level of the sinuses of Valsalva and 3.2 mm larger in athletes versus nonathletes. 5 In the largest cross‐sectional cohort study analyzing AR size in multisport Italian athletes (N=2317), Pelliccia and colleagues observed clinically significant AR dilatation was rare. In a secondary analysis in this study, a control cohort of mixed‐sport athletes (N=115, 62% male) was followed periodically and male athletes demonstrated just 0.7 mm (P<0.01) AR growth over 9±4 years of continuous training. Results from the present study add to our understanding of the effect of sport participation on the aorta. Rigorous and standardized serial imaging assessments over multiple years demonstrate progressive AR dilatation in ASF athletes. Moreover, in contrast to data from Pelliccia, our results suggest there may be strength sport specificity in the context of AR enlargement. Importantly, our findings were repeated measures and aligned with seasonal training versus cross‐sectional, which could be subject to numerous unknown confounders.
Our findings are best interpreted, first, in the context of aortic data taken from retired National Football League athletes. It is well established that retired professional ASF athletes, particularly those with obese playing time body mass index, carry increased cardiovascular risk later in life. 9 , 10 , 25 Intriguingly, in a cohort of 206 retired ASF players, 30% demonstrated clinically significant aortic dilatation and significantly increased ascending aortic size compared with a matched cohort from the Dallas Heart Study‐2. 3 Whether aneurysmal dilatation of the aorta contributes to increased cardiovascular mortality in retired ASF athletes is uncertain. Moreover, whether early AR enlargement, as observed in the present study, predicts later‐life aortic enlargement is also unknown. As such, caution is warranted when applying our data to observations taken from retired ASF athletes. Second, it is also well established that young collegiate ASF athletes manifest early traditional cardiovascular risk, particularly hypertension 11 , 14 , 26 and may develop a maladaptive cardiovascular phenotype 15 consisting of relative arterial stiffening, 13 reduced diastolic function, 14 , 15 ventricular‐arterial uncoupling, 26 and concentric left ventricular hypertrophy. 11 , 15 , 16 Progressive AR dilatation, associated with increased weight, arterial stiffening, and reduced diastolic function further suggests AR enlargement observed in ASF athletes may also be a maladaptive consequence related to traditional early cardiovascular risk. Finally, although AR dilatation is also common in Masters endurance athletes, 2 endurance athletes generally possess lower cardiovascular risk profiles. 27 At present, it is unknown whether youthful endurance athletes develop longitudinal aortic enlargement.
The effect of differences in sport‐specific hemodynamics, dynamic versus static exercise, on AR size is unclear. ASF training is generally characterized by a higher volume of isometric/static exercise, particularly for the lineman player position. 21 Conceptually, the hemodynamic pressure challenge inherent to static training could lead to aortic enlargement. 8 , 28 Indeed, multiple measures of increased arterial stiffening have been reported in young strength‐trained athletes, 28 , 29 , 30 and in the present study we note that AR size is associated with PWV, a measure of central aortic stiffening. However, in other cross‐sectional aortic analyses of athletes, AR size may be larger in endurance‐trained versus strength‐trained athletes. 5 , 7 , 24 As such, strength training may be representative of just 1 contributor to ASF‐associated AR dilatation, but in a more complex and multifactorial process. Other ASF‐specific contributing risk factors could include rapid deliberate weight gain, 21 hypertension 12 or hypertensive response to exercise, and frequent nonsteroidal anti‐inflammatory drug use. 31 Although elite collegiate ASF athletes also typically accrue years of prior ASF exposure in high school, previous data suggest that the temporal acceleration of maladaptive cardiovascular phenotypes occurs after the transition from high school to collegiate ASF. 14
There are important clinical implications taken from these data. First, the presence of early traditional cardiovascular risk associated with changes in cardiovascular phenotypes continues to emphasize the critical need to focus on early preventive efforts, which include counseling, education, and pharmacotherapy when clinically indicated, in young ASF athletes. Second, for ASF athletes with bicuspid aortic valves or incidentally discovered clinically significant AR dilatation, additional clinical adjudication should be pursued in consideration of BP pharmacotherapy or sports eligibility. Maximum effort exercise testing for delineation of exercise BP changes should be considered. Importantly, our results do not support strength training restrictions or competitive sport disqualification for these athletes as none of the athletes in our cohort developed AR >40 mm. 32 Athletes with clinically significant aortic dilatation do warrant more frequent surveillance imaging and clinical follow‐up for elevated blood pressures as well as further investigation for other underlying cardiovascular risk factors. Determination of the appropriate exercise prescription and sports eligibility should ultimately be guided by an athlete‐centered shared decision‐making approach. 33 Future studies are warranted to determine long‐term aortic outcomes in competitive ASF athletes with clinically significant aortic dilatation.
We acknowledge several limitations to this study. First, AR diameter was measured with echocardiography, which can inaccurately measure maximal vessel diameter and be subject to interobserver variability. 34 However, the repeated‐measures design of this study mitigates this limitation. Analysis of aortic size was also limited to AR measurement, although this is typically the most studied aortic dimension and may be more relevant to future acute aortic events. 35 Second, although collegiate ASF training incorporates intense isometric training regimens, we did not quantify exercise load or perform exercise testing to evaluate exercise blood pressure, both of which may theoretically affect AR size. Third, we were unable to evaluate athletes who were lost to attrition and ceased competitive ASF training. This represents a key future research direction to define the cardiovascular changes that may occur with ASF detraining. Fourth, ASF culture includes many unique factors that may influence cardiovascular risk including deliberate weight gain and a high prevalence of nonsteroidal anti‐inflammatory drug use, thus limiting generalizability to other non‐ASF athletes. 21 , 31 Finally, no women were included in this study as National Collegiate Athletic Association ASF athletes are generally all male and we did not include a nonathlete control population.
CONCLUSIONS
ASF athletes develop progressive AR dilatation over the course of the collegiate career. AR dilatation is associated with increased weight, vascular stiffening, and relative reductions in diastolic function, suggesting that increases in AR size may represent a maladaptive structural alteration in young ASF athletes. Future studies are warranted to determine long‐term aortic outcomes in competitive ASF athletes with clinically relevant AR or aortic dilatation.
Sources of Funding
This work was entirely supported by National Institutes of Health/National Heart, Lung, and Blood Institute research grant K23 HL128795 (to Dr Kim). Dr Tso was supported by the Abraham J. & Phyllis Katz Foundation.
Disclosures
Dr Kim receives compensation serving in his role as team cardiologist for the Atlanta Falcons. Dr Baggish receives compensation serving in his role as team cardiologist for the New England Patriots. The remainder of the authors report no financial disclosures.
Acknowledgments
We continue to thank the Athletic Departments and the student‐athletes at Georgia Institute of Technology and Furman University for their ongoing support of this research and participation in our sports registry. We also acknowledge Digirad™ and Athletic Heart™ for providing all echocardiographic imaging services.
This article was sent to Sébastien Bonnet, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.
For Sources of Funding and Disclosures, see page 7.
References
- 1. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73:17–27. doi: 10.1016/S0003-4975(01)03236-2 [DOI] [PubMed] [Google Scholar]
- 2. Churchill TW, Groezinger E, Kim JH, Loomer G, Guseh JS, Wasfy MM, Isselbacher EM, Lewis GD, Weiner RB, Schmied C, et al. Association of ascending aortic dilatation and long‐term endurance exercise among older masters‐level athletes. JAMA Cardiol. 2020;5:522. doi: 10.1001/jamacardio.2020.0054 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Gentry JL III, Carruthers D, Joshi PH, Maroules CD, Ayers CR, de Lemos JA, Aagaard P, Hachamovitch R, Desai MY, Roselli EE, et al. Ascending aortic dimensions in former National Football League athletes. Circ Cardiovasc Imaging. 2017;10:e006852. doi: 10.1161/CIRCIMAGING.117.006852 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Pelliccia A, Di Paolo FM, Quattrini FM. Aortic root dilatation in athletic population. Prog Cardiovasc Dis. 2012;54:432–437. doi: 10.1016/j.pcad.2012.01.004 [DOI] [PubMed] [Google Scholar]
- 5. Iskandar A, Thompson PD. A meta‐analysis of aortic root size in elite athletes. Circulation. 2013;127:791–798. doi: 10.1161/CIRCULATIONAHA.112.000974 [DOI] [PubMed] [Google Scholar]
- 6. Gati S, Malhotra A, Sedgwick C, Papamichael N, Dhutia H, Sharma R, Child AH, Papadakis M, Sharma S. Prevalence and progression of aortic root dilatation in highly trained young athletes. Heart. 2019;105:920–925. doi: 10.1136/heartjnl-2018-314288 [DOI] [PubMed] [Google Scholar]
- 7. Pelliccia A, Di Paolo FM, De Blasiis E, Quattrini FM, Pisicchio C, Guerra E, Culasso F, Maron BJ. Prevalence and clinical significance of aortic root dilation in highly trained competitive athletes. Circulation. 2010;122:698–706. doi: 10.1161/CIRCULATIONAHA.109.901074 [DOI] [PubMed] [Google Scholar]
- 8. Babaee Bigi MA, Aslani A. Aortic root size and prevalence of aortic regurgitation in elite strength trained athletes. Am J Cardiol. 2007;100:528–530. doi: 10.1016/j.amjcard.2007.02.108 [DOI] [PubMed] [Google Scholar]
- 9. Baron SL, Hein MJ, Lehman E, Gersic CM. Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players. Am J Cardiol. 2012;109:889–896. doi: 10.1016/j.amjcard.2011.10.050 [DOI] [PubMed] [Google Scholar]
- 10. Lincoln AE, Vogel RA, Allen TW, Dunn RE, Alexander K, Kaufman ND, Tucker AM. Risk and causes of death among former National Football League players (1986–2012). Med Sci Sports Exerc. 2018;50:486–493. doi: 10.1249/MSS.0000000000001466 [DOI] [PubMed] [Google Scholar]
- 11. Weiner RB, Wang F, Isaacs SK, Malhotra R, Berkstresser B, Kim JH, Hutter AM Jr, Picard MH, Wang TJ, Baggish AL. Blood pressure and left ventricular hypertrophy during American‐style football participation. Circulation. 2013;128:524–531. doi: 10.1161/CIRCULATIONAHA.113.003522 [DOI] [PubMed] [Google Scholar]
- 12. Karpinos AR, Roumie CL, Nian H, Diamond AB, Rothman RL. High prevalence of hypertension among collegiate football athletes. Circ Cardiovasc Qual Outcomes. 2013;6:716–723. doi: 10.1161/CIRCOUTCOMES.113.000463 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Kim JH, Sher S, Wang F, Berkstresser B, Shoop JL, Galante A, Al Mheid I, Ghasemzadeh N, Hutter AM, Williams BR III, et al. Impact of American‐style football participation on vascular function. Am J Cardiol. 2015;115:262–267. doi: 10.1016/j.amjcard.2014.10.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Kim JH, Hollowed C, Patel K, Hosny K, Aida H, Gowani Z, Sher S, Shoop JL, Galante A, Clark C, et al. Temporal changes in cardiovascular remodeling associated with football participation. Med Sci Sports Exerc. 2018;50:1892–1898. doi: 10.1249/MSS.0000000000001631 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Kim JH, Hollowed C, Liu C, Al‐Badri A, Alkhoder A, Dommisse M, Gowani Z, Miller A, Nguyen P, Prabakaran G, et al. Weight gain, hypertension, and the emergence of a maladaptive cardiovascular phenotype among US football players. JAMA Cardiol. 2019;4:1221–1229. doi: 10.1001/jamacardio.2019.3909 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Lin J, Wang F, Weiner RB, DeLuca JR, Wasfy MM, Berkstresser B, Lewis GD, Hutter AM Jr, Picard MH, Baggish AL. Blood pressure and LV remodeling among American‐style football players. JACC Cardiovasc Imaging. 2016;9:1367–1376. doi: 10.1016/j.jcmg.2016.07.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Croft LB, Belanger A, Miller MA, Roberts A, Goldman ME. Comparison of National Football League linemen versus nonlinemen of left ventricular mass and left atrial size. Am J Cardiol. 2008;102:343–347. doi: 10.1016/j.amjcard.2008.03.065 [DOI] [PubMed] [Google Scholar]
- 18. Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14. doi: 10.1016/j.echo.2014.10.003 [DOI] [PubMed] [Google Scholar]
- 19. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1–64. doi: 10.1016/j.echo.2018.06.004 [DOI] [PubMed] [Google Scholar]
- 20. Engel DJ, Schwartz A, Homma S. Athletic cardiac remodeling in US professional basketball players. JAMA Cardiol. 2016;1:80–87. doi: 10.1001/jamacardio.2015.0252 [DOI] [PubMed] [Google Scholar]
- 21. Kim JH, Zafonte R, Pascuale‐Leon A, Nadler LM, Weisskopf M, Speizer FE, Taylor HA, Baggish AL. American‐style football and cardiovascular health. J Am Heart Assoc. 2018;7:e008620. doi: 10.1161/JAHA.118.008620 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Reference Values for Arterial Stiffness' Collaboration . Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31:2338–2350. doi: 10.1093/eurheartj/ehq165 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. D'Andrea A, Cocchia R, Riegler L, Scarafile R, Salerno G, Gravino R, Vriz O, Citro R, Limongelli G, Di Salvo G, et al. Aortic root dimensions in elite athletes. Am J Cardiol. 2010;105:1629–1634. doi: 10.1016/j.amjcard.2010.01.028 [DOI] [PubMed] [Google Scholar]
- 24. Boraita A, Heras ME, Morales F, Marina‐Breysse M, Canda A, Rabadan M, Barriopedro MI, Varela A, de la Rosa A, Tuñón J. Reference values of aortic root in male and female white elite athletes according to sport. Circ Cardiovasc Imaging. 2016;9:e005292. doi: 10.1161/CIRCIMAGING.116.005292 [DOI] [PubMed] [Google Scholar]
- 25. Nguyen VT, Zafonte RD, Chen JT, Kponee‐Shovein KZ, Paganoni S, Pascual‐Leone A, Speizer FE, Baggish AL, Taylor HA Jr, Nadler LM, et al. Mortality among professional American‐style football players and professional American baseball players. JAMA Netw Open. 2019;2:e194223. doi: 10.1001/jamanetworkopen.2019.4223 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Tso JV, Turner CG, Liu C, Ahmad S, Ali A, Selvaraj S, Galante A, Gilson CR, Clark C, Williams BR III, et al. Hypertension and ventricular–arterial uncoupling in collegiate American football athletes. J Am Heart Assoc. 2022;11:e023430. doi: 10.1161/JAHA.121.023430 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Lee DC, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. Leisure‐time running reduces all‐cause and cardiovascular mortality risk. J Am Coll Cardiol. 2014;64(5):472–481. doi: 10.1016/j.jacc.2014.04.058 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. D'Andrea A, Cocchia R, Riegler L, Salerno G, Scarafile R, Citro R, Vriz O, Limongelli G, Di Salvo G, Caso P, et al. Aortic stiffness and distensibility in top‐level athletes. J Am Soc Echocardiogr. 2012;25:561–567. doi: 10.1016/j.echo.2011.12.021 [DOI] [PubMed] [Google Scholar]
- 29. Otsuki T, Maeda S, Iemitsu M, Saito Y, Tanimura Y, Ajisaka R, Miyauchi T. Relationship between arterial stiffness and athletic training programs in young adult men. Am J Hypertens. 2007;20:967–973. doi: 10.1016/j.amjhyper.2007.05.001 [DOI] [PubMed] [Google Scholar]
- 30. Bertovic DA, Waddell TK, Gatzka CD, Cameron JD, Dart AM, Kingwell BA. Muscular strength training is associated with low arterial compliance and high pulse pressure. Hypertension. 1999;33:1385–1391. doi: 10.1161/01.HYP.33.6.1385 [DOI] [PubMed] [Google Scholar]
- 31. Tso J, Hollowed C, Liu C, Alkhoder A, Dommisse M, Gowani Z, Miller A, Nguyen G, Nguyen P, Prabakaran G, et al. Nonsteroidal anti‐inflammatory drugs and cardiovascular risk in American football. Med Sci Sports Exerc. 2020;52:2522–2528. doi: 10.1249/MSS.0000000000002404 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Galanti G, Stefani L, Toncelli L, Vono MC, Mercuri R, Maffulli N. Effects of sports activity in athletes with bicuspid aortic valve and mild aortic regurgitation. Br J Sports Med. 2010;44:275–279. doi: 10.1136/bjsm.2008.047407 [DOI] [PubMed] [Google Scholar]
- 33. Martinez MW, Kim JH, Shah AB, Phelan D, Emery MS, Wasfy MM, Fernandez AB, Bunch TJ, Dean P, Danielian A, et al. Exercise‐induced cardiovascular adaptations and approach to exercise and cardiovascular disease: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2021;78:1453–1470. doi: 10.1016/j.jacc.2021.08.003 [DOI] [PubMed] [Google Scholar]
- 34. Vonder M, Willems TP, Van Melle JP, Elzenga NJ, Ebels T. True diameter of vessels. J Am Soc Echocardiogr. 2014;27:448–449. doi: 10.1016/j.echo.2014.01.003 [DOI] [PubMed] [Google Scholar]
- 35. Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, Elefteriades JA. Root dilatation is more malignant than ascending aortic dilation. J Am Heart Assoc. 2021;10:e020645. doi: 10.1161/JAHA.120.020645 [DOI] [PMC free article] [PubMed] [Google Scholar]